illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Panion & BF Biotech
Company logo

Panion & BF Biotech | Sustainability Performance

http://www.pbf.com.tw/

Biopharmaceutical company focused on biotechnology products and pharmaceuticals.

1976

Taiwan

201 - 500 employees

Pharmaceuticals

$25M - 100M in revenue

$1M - 10M in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#6694
Overall
#89
in Taiwan
#150
in Pharmaceuticals

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

268 out of 311

Overview
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Scinopharm Taiwan

Taiwan, Health Care, Pharmaceuticals


Company logo
Sinphar Pharmaceutical

Taiwan, Health Care, Pharmaceuticals


Company logo
TCI

Taiwan, Health Care, Biotechnology

Market cap

5.3B $, 2026▲15.4% YoY

Revenue

2.1B $, 2025▼1.6% YoY

R&D intensity

9.45% 2025

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

5.3B $, 2026▲15.4% YoY

Revenue

2.1B $, FY2025▼1.6% YoY

EBITDA

307.0M $, FY2025▼9.1% YoY

Operating margin

15% Industry: -33▼32.1% YoY

P/E ratio

28.5 Industry: 26▲98.8% YoY

Revenue & EBITDA

$2.1BFY2025 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

151.2M 2025▲9.4% YoY

Capex

158.0M 2025▲17.1% YoY

Debt/equity ratio

0.3 Industry: 0▼NaN% YoY

R&D intensity

9.4%FY2025

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

7.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

1.9

▼ 7.7%

2023

2.0

▼ 3.6%

2024

2.1

▲ 0.5%

2025

2.1

2026

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Not available

20%
Independent Directors

3 out of 15 incl. management

Powered by illuminem

Overall score

0

Environment

0

Social

0

Governance

0

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees


    Available in
    Scale package

    Access
  • Email

  • Email